This article reviews current ESC guidance on the management of concomitant atrial fibrillation and coronary artery disease, highlighting antithrombotic risk assessment and treatment strategies.
Reviews antithrombotic options in AF with CAD; leaves open optimal regimens pending dedicated trials.
Atrial fibrillation ( AF ) is the most common sustained cardiac arrhythmia and associated with significant morbidity and mortality. Coronary artery disease ( CAD ) frequently coexists with AF , and management of these associated conditions can be challenging. Bleeding risks of different combinations of evidence‐based antithrombotic regimes need to be considered and the effects of different medical therapies for AF or CAD may impact on the other condition. This article reviews the current guidance and consensus statements of the ESC on the management of AF and CAD . The principles of AF management in the context of CAD are considered including upstream therapies to prevent AF , early identification, and antithrombotic risk assessment, and symptomatic rate and rhythm control strategies. Specific scenarios and an illustrative case are discussed to highlight clinical relevance. Answer questions and earn CME: https://wileyhealthlearning.com/Activity2/5381990/Activity.aspx
No takes yet. Share an insight, caveat, or question.
Martin et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: